JP2022515194A5 - - Google Patents
Info
- Publication number
- JP2022515194A5 JP2022515194A5 JP2021536031A JP2021536031A JP2022515194A5 JP 2022515194 A5 JP2022515194 A5 JP 2022515194A5 JP 2021536031 A JP2021536031 A JP 2021536031A JP 2021536031 A JP2021536031 A JP 2021536031A JP 2022515194 A5 JP2022515194 A5 JP 2022515194A5
- Authority
- JP
- Japan
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2024046429A JP7843056B2 (ja) | 2018-12-19 | 2024-03-22 | Ｔ細胞リンパ腫およびｔ細胞白血病に対するｃｄ２／５／７ノックアウト抗ｃｄ２／５／７キメラ抗原受容体ｔ細胞の使用 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862782131P | 2018-12-19 | 2018-12-19 | |
| US62/782,131 | 2018-12-19 | ||
| PCT/US2019/067613 WO2020132327A1 (en) | 2018-12-19 | 2019-12-19 | Use of cd2/5/7 knock-out anti-cd2/5/7 chimeric antigen receptor t cells against t cell lymphomas and leukemias |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024046429A Division JP7843056B2 (ja) | 2018-12-19 | 2024-03-22 | Ｔ細胞リンパ腫およびｔ細胞白血病に対するｃｄ２／５／７ノックアウト抗ｃｄ２／５／７キメラ抗原受容体ｔ細胞の使用 |
Publications (4)
| Publication Number | Publication Date |
|---|---|
| JP2022515194A JP2022515194A (ja) | 2022-02-17 |
| JPWO2020132327A5 JPWO2020132327A5 (https=) | 2022-12-26 |
| JP2022515194A5 true JP2022515194A5 (https=) | 2022-12-26 |
| JP7620374B2 JP7620374B2 (ja) | 2025-01-23 |
Family
ID=71102914
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021536031A Active JP7620374B2 (ja) | 2018-12-19 | 2019-12-19 | Ｔ細胞リンパ腫およびｔ細胞白血病に対するｃｄ２／５／７ノックアウト抗ｃｄ２／５／７キメラ抗原受容体ｔ細胞の使用 |
| JP2024046429A Active JP7843056B2 (ja) | 2018-12-19 | 2024-03-22 | Ｔ細胞リンパ腫およびｔ細胞白血病に対するｃｄ２／５／７ノックアウト抗ｃｄ２／５／７キメラ抗原受容体ｔ細胞の使用 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024046429A Active JP7843056B2 (ja) | 2018-12-19 | 2024-03-22 | Ｔ細胞リンパ腫およびｔ細胞白血病に対するｃｄ２／５／７ノックアウト抗ｃｄ２／５／７キメラ抗原受容体ｔ細胞の使用 |
Country Status (11)
| Country | Link |
|---|---|
| US (3) | US11673964B2 (https=) |
| EP (1) | EP3898692A4 (https=) |
| JP (2) | JP7620374B2 (https=) |
| KR (1) | KR20220002859A (https=) |
| CN (2) | CN113454117B (https=) |
| AU (1) | AU2019404302A1 (https=) |
| CA (1) | CA3124467A1 (https=) |
| IL (1) | IL284196A (https=) |
| MX (1) | MX2021007547A (https=) |
| SG (1) | SG11202106699VA (https=) |
| WO (1) | WO2020132327A1 (https=) |
Families Citing this family (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MX2014010185A (es) * | 2012-02-22 | 2014-11-14 | Univ Pennsylvania | Uso de dominio de señalizacion cd2 en receptores de antigeno quimericos de segunda generacion. |
| US20170151281A1 (en) | 2015-02-19 | 2017-06-01 | Batu Biologics, Inc. | Chimeric antigen receptor dendritic cell (car-dc) for treatment of cancer |
| WO2020168122A1 (en) | 2019-02-13 | 2020-08-20 | Beam Therapeutics Inc. | Modified immune cells having adenosine deaminase base editors for modifying a nucleobase in a target sequence |
| EP4034138A4 (en) | 2019-09-27 | 2024-07-31 | Beam Therapeutics, Inc. | COMPOSITIONS AND METHODS FOR THE TREATMENT OF LIQUID CANCERS |
| US10980836B1 (en) | 2019-12-11 | 2021-04-20 | Myeloid Therapeutics, Inc. | Therapeutic cell compositions and methods of manufacturing and use thereof |
| WO2022061115A1 (en) * | 2020-09-18 | 2022-03-24 | Vor Biopharma Inc. | Compositions and methods for cd7 modification |
| AU2021347359A1 (en) * | 2020-09-25 | 2023-05-18 | Beam Therapeutics Inc. | Fratricide resistant modified immune cells and methods of using the same |
| CN116568709A (zh) * | 2020-11-01 | 2023-08-08 | 南京驯鹿生物技术股份有限公司 | 靶向cd5的全人源抗体、全人源嵌合抗原受体（car）及其应用 |
| CA3197423A1 (en) | 2020-11-04 | 2022-05-12 | Daniel Getts | Engineered chimeric fusion protein compositions and methods of use thereof |
| EP4279515A4 (en) * | 2021-01-12 | 2025-02-19 | Nanjing Iaso Biotechnology Co., Ltd. | Fully human single-domain tandem chimeric antigen receptor (car) targeting cd5, and use thereof |
| CA3207861A1 (en) * | 2021-02-11 | 2022-08-18 | Carl H. June | Ccr4-targeting chimeric antigen receptor cell therapy |
| CN115044617B (zh) * | 2021-03-08 | 2024-08-13 | 河北森朗生物科技有限公司 | Car t细胞的制备方法、car t细胞及其应用 |
| EP4308133A4 (en) | 2021-03-17 | 2025-01-22 | Myeloid Therapeutics, Inc. | MANIPULATED CHIMERIC FUSION PROTEIN COMPOSITIONS AND METHODS OF USE THEREOF |
| AU2022272235A1 (en) | 2021-05-11 | 2023-12-21 | Create Medicines, Inc. | Methods and compositions for genomic integration |
| CN115989244A (zh) * | 2021-08-06 | 2023-04-18 | 上海驯鹿生物技术有限公司 | Cd5和cd7双靶点的全人源嵌合抗原受体(car)及其应用 |
| CA3240846A1 (en) * | 2021-12-14 | 2023-06-22 | The Trustees Of The University Of Pennsylvania | Cd5 modified cells comprising chimeric antigen receptors (cars) for treatment of solid tumors |
| CN114645022B (zh) * | 2022-05-13 | 2022-09-02 | 首都医科大学宣武医院 | 靶向CD5的CAR-γ δ T细胞及其制备方法与应用 |
| CN117431217A (zh) * | 2022-07-12 | 2024-01-23 | 上海驯鹿生物技术有限公司 | 表达靶向cd5的嵌合抗原受体(car)的细胞及其应用 |
| KR102869461B1 (ko) * | 2022-10-05 | 2025-10-17 | 주식회사 지씨셀 | Cd5를 표적하는 키메라 항원 수용체 및 이를 발현하는 면역세포 |
| KR20260051108A (ko) * | 2023-05-23 | 2026-04-15 | 비토리아 바이오테라퓨틱스, 인코포레이티드. | Cd5 유전자좌 영역에 삽입된 이종성 핵산 분자를 포함하는 유전자 변형 세포 |
| EP4719467A2 (en) * | 2023-05-31 | 2026-04-08 | Vittoria Biotherapeutics, Inc. | Methods of manufacturing t cells |
| CN119529071B (zh) * | 2023-08-28 | 2025-11-18 | 东莞市朋志生物科技有限公司 | 一种抗登革病毒或其ns1蛋白的抗体及其应用 |
| WO2025122896A1 (en) * | 2023-12-08 | 2025-06-12 | The Trustees Of The University Of Pennsylvania | Cd5 modified cells comprising heterologous tcrs and methods of using the same |
| CN118891290A (zh) * | 2024-04-12 | 2024-11-01 | 科济生物医药（上海）有限公司 | 细胞免疫疗法的组合物和方法 |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5951983A (en) | 1993-03-05 | 1999-09-14 | Universite Catholique De Louvain | Methods of inhibiting T cell mediated immune responses with humanized LO-CD2A-specific antibodies |
| MX2011000970A (es) | 2008-08-29 | 2011-03-15 | Symphogen As | Anticuerpos anti-cd5. |
| US11047010B2 (en) * | 2014-02-06 | 2021-06-29 | Immunexpress Pty Ltd | Biomarker signature method, and apparatus and kits thereof |
| JP7237449B2 (ja) | 2015-02-27 | 2023-03-13 | アイセル・ジーン・セラピューティクス・エルエルシー | 血液系腫瘍を標的としたキメラ抗体受容体（ＣＡＲｓ）の構成およびその使用方法 |
| WO2017112877A1 (en) | 2015-12-22 | 2017-06-29 | Icell Gene Therapeutics, Llc | Chimeric antigen receptors and enhancement of anti-tumor activity |
| WO2017172981A2 (en) * | 2016-03-29 | 2017-10-05 | University Of Southern California | Chimeric antigen receptors targeting cancer |
| EP3448874A4 (en) * | 2016-04-29 | 2020-04-22 | Voyager Therapeutics, Inc. | COMPOSITIONS FOR TREATING A DISEASE |
| CN110352068A (zh) | 2016-12-02 | 2019-10-18 | 南加利福尼亚大学 | 合成的免疫受体及其使用方法 |
| WO2018156180A1 (en) * | 2017-02-24 | 2018-08-30 | Kindred Biosciences, Inc. | Anti-il31 antibodies for veterinary use |
| EP4414380A3 (en) * | 2017-03-31 | 2024-12-04 | Cellectis SA | Universal anti-cd22 chimeric antigen receptor engineered immune cells |
| CA3065126A1 (en) * | 2017-06-01 | 2018-12-06 | Innovative Cellular Therapeutics CO., LTD. | Chimeric antigen receptor cell preparation and uses thereof |
-
2019
- 2019-12-19 WO PCT/US2019/067613 patent/WO2020132327A1/en not_active Ceased
- 2019-12-19 MX MX2021007547A patent/MX2021007547A/es unknown
- 2019-12-19 EP EP19898610.1A patent/EP3898692A4/en active Pending
- 2019-12-19 CA CA3124467A patent/CA3124467A1/en active Pending
- 2019-12-19 CN CN201980092281.9A patent/CN113454117B/zh active Active
- 2019-12-19 AU AU2019404302A patent/AU2019404302A1/en active Pending
- 2019-12-19 CN CN202510805788.1A patent/CN121059792A/zh active Pending
- 2019-12-19 JP JP2021536031A patent/JP7620374B2/ja active Active
- 2019-12-19 US US17/416,365 patent/US11673964B2/en active Active
- 2019-12-19 KR KR1020217022614A patent/KR20220002859A/ko active Pending
- 2019-12-19 SG SG11202106699VA patent/SG11202106699VA/en unknown
-
2021
- 2021-06-20 IL IL284196A patent/IL284196A/en unknown
-
2023
- 2023-04-21 US US18/304,843 patent/US20230331864A1/en active Pending
-
2024
- 2024-03-22 JP JP2024046429A patent/JP7843056B2/ja active Active
- 2024-03-28 US US18/620,748 patent/US12227588B2/en active Active